Physician profile
Corneliu Luca
NPI 1578711305
$257,142.84
in general payments reported to CMS, 2019-2025
23 companies · $54K in 2025
The $54K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $39K · 2021: $14K · 2022: $31K · 2023: $12K · 2024: $21K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $22K · Consulting Fee: $12K · Food and Beverage: $5,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,755.00 |
| Travel and Lodging | $22,098.42 |
| Consulting Fee | $12,243.24 |
| Food and Beverage | $5,679.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $98,568.36 | 2019-2025 | Vercise, General - Dbs |
| Abbott Laboratories | $69,579.98 | 2019-2025 | Infinity |
| Medtronic, INC. | $32,514.19 | 2019-2025 | Percept PC Brainsense, Activa PC |
| Abbvie INC. | $12,897.19 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $10,526.75 | 2019-2025 | Rytary, Crexont, Ongentys |
| Medtronic USA, INC. | $9,381.62 | 2019-2020 | |
| Kyowa Kirin, INC. | $6,210.69 | 2019-2020 | |
| Mdd US Operations, LLC | $4,035.64 | 2019-2024 | Apokyn |
| Acadia Pharmaceuticals INC | $4,015.06 | 2019-2021 | |
| Acorda Therapeutics, INC | $3,985.94 | 2020-2024 | Inbrija |
| Insightec,INC | $981.44 | 2020-2025 | Exablate |
| Vertex Pharmaceuticals Incorporated | $962.50 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $960.00 | 2025 | |
| Cala Health, INC. | $900.00 | 2022 | |
| Neurocrine Biosciences, INC. | $511.66 | 2019-2024 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $351.40 | 2020 | |
| Celgene Corporation | $299.20 | 2025 | |
| Merz Pharmaceuticals, LLC | $188.61 | 2024-2025 | Xeomin, Inbrija |
| Amgen INC. | $183.42 | 2019-2020 | |
| Lilly USA, LLC | $34.75 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $34.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corneliu Luca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.